Noble Life Appoints Chief Scientific Officer
The company has also appointed Jeffrey Strovel as the vice president of translational medicine and Stephen Garvey as vice president of laboratory resources and services.
During his tenure at Avalon, Mr Horrigan held several positions of increasing responsibility within the research organization while directing both internal and collaborative research programs. He also played a key leadership role in the development of the company's unique genomic biomarker-driven R&D platform.
Previously, Mr Strovel was the head of discovery research at Avalon Pharmaceuticals where he was instrumental in developing many of the company's novel biomarker-driven discovery systems.
At Avalon, Mr Strovel also led discovery efforts which resulted in the identification of the company's seminal product development candidate, a mechanistically novel cancer drug candidate targeting a major, previously intractable, target pathway in colorectal cancer.
For eight years prior to the inception of Noble, Mr. Garvey oversaw vivarium services at Avalon Pharmaceuticals and managed research contracts for housing and husbandry clients. He also has held positions at Human Genome Sciences, GlaxoSmithKline, and the Philadelphia College of Osteopathic Medicine.
Kenneth Carter, president and CEO of Noble Life Sciences, said: â€œWe are delighted that Mr Horrigan has joined our team. He is an accomplished molecular geneticist who is known for his contributions to the development of innovative approaches for using genomic profiles and biomarkers to enhance drug discovery and development.
â€œMr Horrigan has strong expertise in cellular control mechanisms of cancer and the use of biomarkers for discovery and development of therapeutics. He will be invaluable in providing biomarker validation services and guidance on pre-clinical drug development to our clients.â€
Will these changes benefit the firm?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.